A Phase 1 interventional study of vabicaserin in Schizophrenia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-12-05.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer · Phase 1, Interventional, and Health services research
The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
Browse Schizophrenia studies →Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 472 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Assess the bioavailability of four oral formulations of vabicaserin.
Obtain additional safety and tolerability data for vabicaserin in healthy male subjects.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyeth is now a wholly owned subsidiary of Pfizer